Publications:
Our Research

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without human immunodeficiency virus type 1 infection

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

NVX-CoV2373 Vaccine for COVID-19

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine